Epoprostenol therapy for pulmonary arterial hypertension

Satoshi Akagi, Kazufumi Nakamura, Hiromi Matsubara, Aiko Ogawa, Toshihiro Sarashina, Kentaro Ejiri, Hiroshi Itoh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.

Original languageEnglish
Pages (from-to)129-136
Number of pages8
JournalActa Medica Okayama
Volume69
Issue number3
Publication statusPublished - 2015

Fingerprint

Epoprostenol
Pulmonary Hypertension
Pulmonary Artery
Therapeutics
Pulmonary Veno-Occlusive Disease
Catheter-Related Infections
Lung
Connective Tissue Diseases
Catheters
Hemodynamics
Portal Hypertension
Vasoconstriction
Vasodilator Agents
Hypotension
Headache
Heart Diseases
Heart Failure
Tissue
Pressure

Keywords

  • Complications
  • Epoprostenol
  • High-dose
  • Pulmonary arterial hypertension
  • Side effects

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Akagi, S., Nakamura, K., Matsubara, H., Ogawa, A., Sarashina, T., Ejiri, K., & Itoh, H. (2015). Epoprostenol therapy for pulmonary arterial hypertension. Acta Medica Okayama, 69(3), 129-136.

Epoprostenol therapy for pulmonary arterial hypertension. / Akagi, Satoshi; Nakamura, Kazufumi; Matsubara, Hiromi; Ogawa, Aiko; Sarashina, Toshihiro; Ejiri, Kentaro; Itoh, Hiroshi.

In: Acta Medica Okayama, Vol. 69, No. 3, 2015, p. 129-136.

Research output: Contribution to journalArticle

Akagi, S, Nakamura, K, Matsubara, H, Ogawa, A, Sarashina, T, Ejiri, K & Itoh, H 2015, 'Epoprostenol therapy for pulmonary arterial hypertension', Acta Medica Okayama, vol. 69, no. 3, pp. 129-136.
Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K et al. Epoprostenol therapy for pulmonary arterial hypertension. Acta Medica Okayama. 2015;69(3):129-136.
Akagi, Satoshi ; Nakamura, Kazufumi ; Matsubara, Hiromi ; Ogawa, Aiko ; Sarashina, Toshihiro ; Ejiri, Kentaro ; Itoh, Hiroshi. / Epoprostenol therapy for pulmonary arterial hypertension. In: Acta Medica Okayama. 2015 ; Vol. 69, No. 3. pp. 129-136.
@article{c4cee782cb354bdca4c0ebe0654ea729,
title = "Epoprostenol therapy for pulmonary arterial hypertension",
abstract = "Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.",
keywords = "Complications, Epoprostenol, High-dose, Pulmonary arterial hypertension, Side effects",
author = "Satoshi Akagi and Kazufumi Nakamura and Hiromi Matsubara and Aiko Ogawa and Toshihiro Sarashina and Kentaro Ejiri and Hiroshi Itoh",
year = "2015",
language = "English",
volume = "69",
pages = "129--136",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Epoprostenol therapy for pulmonary arterial hypertension

AU - Akagi, Satoshi

AU - Nakamura, Kazufumi

AU - Matsubara, Hiromi

AU - Ogawa, Aiko

AU - Sarashina, Toshihiro

AU - Ejiri, Kentaro

AU - Itoh, Hiroshi

PY - 2015

Y1 - 2015

N2 - Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.

AB - Pulmonary arterial hypertension (PAH) is characterized by elevation of pulmonary artery pressure caused by pulmonary vasoconstriction and vascular remodeling, which leads to right heart failure and death. Epoprostenol (prostaglandin I2) has a potent short-acting vasodilator property, and intravenous continuous epoprostenol is therefore used for treatment of PAH. Here we review evidence for the usefulness of intravenous continuous epoprostenol therapy in patients with PAH. Epoprostenol therapy is effective in idiopathic PAH patients and in patients with PAH associated with connective tissue disease, portal hypertension or congenital heart diseases, but it is not effective in patients with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis. High-dose epoprostenol therapy markedly improved hemodynamics in some patients with PAH, possibly due to reverse remodeling of pulmonary arteries. This therapy has several side effects and complications such as headache, hypotension and catheter-related infections. Intravenous continuous epoprostenol is an effective treatment, but there are still some problems to be resolved.

KW - Complications

KW - Epoprostenol

KW - High-dose

KW - Pulmonary arterial hypertension

KW - Side effects

UR - http://www.scopus.com/inward/record.url?scp=84937043038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937043038&partnerID=8YFLogxK

M3 - Article

C2 - 26101188

AN - SCOPUS:84937043038

VL - 69

SP - 129

EP - 136

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -